Kaplan-Meier Curves for Overall Survival and Progression Free Survival according to TS mRNA levels.

<p>Kaplan-Meier Curves for Overall Survival and Progression Free Survival according to TS mRNA levels.</p

Overall survival according to Ki67.

<p>Overall survival according to Ki67.</p

Kaplan Meier Curves for Overall Survival and Progression Free Survival.

<p>Kaplan Meier Curves for Overall Survival and Progression Free Survival.</p

Patient characteristics.

<p>Patient characteristics.</p

Additional file 5: Figure S2. of Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

The effect of HERC2 mRNA expression on the outcome of patients expressing high levels of BRCA1. (DOCX 198 kb

Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s41030-016-0013-3">https://link.springer.com/article/10.1007/s41030-016-0013-3</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Comparison of sensitivity to various drugs between erlotinib- and gefitinib- resistant cell lines and their drug sensitive parental counterparts, PC9 and 11–18 cells.

a)<p>IC50 values are calulated from logit regression line from triplicate assays. IC50 values (µM) for erlotinib, gefitinib, lapatinib, SU11274, BIBW2992 and cisplatin are 0.04, 0.03, 3.16, 3.97, 0.00021 and 2.07 in PC9, 9.96, 5.04, 14.54, 3.97, 0.41 and 2.89 in PC9/ER1, 0.87, 0.32, 2.57, 4.22, 0.35 and 5.37 in 11–18, 20.88, 8.32, 2.83, 4.64, 0.49 and 1.61 in 11–18/ER1-7, 95.7, 20.48, 4.11, 5.06, 0.74 and 9.13 in 11–18/ER2-1, >29.58, 11.52, 13.36, 3.38 and 2.41 in 11–18/GEF10-1, and >29.58, 10.24, 14.14, 3.80 and 1.61 in 11–18/GEF20-1 respectively. The relative resistance is defined as the IC50 value divided by the IC50 value of the parental PC9 or 11–18.</p>b)<p>nt, not tested.</p

The effect of PI3K inhibitors and PIK3CA knockdown on PC9 and PC9/ER1 cells.

<p>A, B, Exponentially growing PC9 and PC9/ER1 cells were exposed to various doses of wortmannin (A) and LY294002 (B) for 5 hr, and followed by Western blot analysis. C. PC9 and PC9/ER1 cells were treated with PIK3CA siRNA or scramble (SC) siRNA for 48 h, and followed by western blot analysis.</p

Immunostaining images for EGFR expression in both histological and cytological samples in human NSCLC.

<p>Total EGFR antibody stained all four histological and cytological samples. Anti-delE746-A750 antibody stained only cancer cells with the delE746-A750 mutation (A, case 1) (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0041017#pone-0041017-t002" target="_blank">Table 2</a>), and the EGFR L858R antibody stained only cancer cells with the L858R mutations (B, case 9) in both histological and cytological samples. No staining was evident by both EGFR delE746-A750 and EGFR L858R antibodies in cancer cells without the activating EGFR mutations in cytological samples (C: case 6 and D: case 11).</p

The effect of erlotinib, lapatinib and BIBW2992 on phosphorylation of Akt and EGFR family proteins in PC9/ER1 cells.

<p>A, PC9/ER1 cells were treated with or without 1 µM erlotinib, and 5 µM lapatinib for 5 hrs, and followed Western blot analysis. B, PC9/ER1 cells were treated with 10 nM of siRNAs of scrumble and EGFR family genes, and exposed to erlotinib (1 µM) or BIBW2992 (1 µM) for 5 hrs, and followed Western blot analysis.</p